Silicon Valley longevity scene turns to grey-market peptides as FDA plans 2026 reclassification of about 14 compounds
Silicon Valley's longevity crowd is buying peptides off grey markets, some imported from China with no purity guarantees. Two women were hospitalized on ventilators in 2025 after injections at a Las Vegas longevity conference. The FDA now plans to reclassify about 14 peptides in
The longevity obsession running through tech circles has a new fixation: peptides. These are a broad class of injectable and oral compounds, ranging from FDA-approved medications to unregulated products imported from China and sold across mainstream online retail platforms. The appeal is the promise of better recovery, performance and appearance. The problem is the supply chain. Compounds bought through grey-market channels come with no guarantee of purity, correct dosing or accurate labeling, and contamination is a real risk. In 2025, two women were hospitalized and placed on ventilators after receiving peptide injections at a longevity conference in Las Vegas, though it remains unclear whether they reacted to the peptides themselves or to an impurity in the vials. Regulators are now shifting course. The FDA intends to move roughly 14 of 19 peptides from a restricted category back to one that allows pharmacy compounding in 2026, a change framed by supporters as a way to pull buyers out of unregulated markets that the previous restrictions helped create. For anyone considering these compounds, the gap between a regulated prescription and an unverified vial bought online is the difference that matters most.